Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

While Gilead’s Tecartus and Novartis’ Kymriah also boast approvals in ALL, Autolus’ new med boasts a unique edge as the only CAR-T that doesn’t come with an FDA requirement for a Risk Evaluation ...

Novartis previously signed an agreement with CellforCure in July to produce CAR-T cell therapies including Kymriah (tisagenlecleucel) – which was the first CAR-T cell therapy approved by the FDA ...

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with ...

Senator asks Novartis to explain its payments to Cohen, noting FDA approval of cancer drug Novartis made $1.2 million in payments to Cohen's firm during the time that the FDA was deciding whether ...

An FDA announcement last year of an investigation into the risk of patients developing secondary cancers following the ...

Swiss pharmaceuticals group Novartis has said it will charge $475,000 ... the drug, known as Kymriah, is the most expensive to go on sale. Strigini pointed out the price tag was below the ...

LEGN)), and Novartis’ Kymriah. These therapies are individually approved for multiple myeloma, large B-cell lymphoma, and other blood cancers. The FDA specifically instructs the companies to ...

The focus of the probe may be Novartis AG’s Kymriah, RBC Capital Markets analysts led by Brian Abrahams said in a note to clients. The regulator’s adverse events database points to the therapy ...

With the AveXis and Endocyte deals - as well as Novartis's ongoing work with Kymriah - Novartis has managed to extend its reach into a number of buzzy new areas of biotech, from gene therapies to ...

The US regulatory body’s decision was based on the results of a Novartis-sponsored clinical trial, in which 52 of 63 patients (83%) who received the Kymriah treatment achieved remission from ...

A cutting-edge new cancer treatment from Novartis called Kymriah just got approved to treat more people with certain blood cancers last week, the drug's second approval. The new approval - this ...